HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Metastatic malignant neoplasm to trunk — Clinical Guidelines

Overview

Metastatic malignant neoplasms affecting the trunk represent advanced stages of cancer dissemination, often involving the pelvis, spine, and other axial skeleton regions. These metastases frequently cause significant pain, functional impairment, and diminished quality of life for patients. The trunk, particularly areas like the pelvis and sacrum, is prone to extensive bone destruction and soft tissue involvement, necessitating multidisciplinary management strategies. Effective treatment requires a balance between palliative care to alleviate symptoms and aggressive interventions to stabilize the patient's condition. Understanding the nuances of surgical and non-surgical management is crucial for clinicians to optimize patient outcomes and improve survival rates. This matters in day-to-day practice as early recognition and tailored interventions can significantly impact both the morbidity and mortality associated with these conditions 1 3 7.

Pathophysiology

The pathophysiology of metastatic malignant neoplasms in the trunk involves complex interactions at cellular and molecular levels. Primary tumors release circulating tumor cells that seed in distant organs, including the axial skeleton, facilitated by factors such as angiogenesis, immune evasion, and metastatic niche formation. Once lodged, these cells adapt to the new microenvironment, often supported by local bone remodeling processes like osteolysis and osteoblastic reactions, leading to structural instability and pain. In the context of the pelvis, metastatic lesions frequently affect weight-bearing areas of the acetabulum, causing extensive bone loss and potential pathological fractures 1 3. The surrounding soft tissues may also be infiltrated or compressed, exacerbating functional deficits and necessitating comprehensive reconstructive approaches.

Epidemiology

The incidence of metastatic disease in the trunk varies by primary tumor type but generally increases with advanced cancer stages. Prostate, breast, lung, and renal cancers are common sources of such metastases. Epidemiological studies indicate that the pelvis is the second most frequent site after the spine, with a higher prevalence in older adults, reflecting the typical age of onset for many primary malignancies 1. Geographic and socioeconomic factors can influence access to early detection and treatment, thereby affecting incidence rates. Trends over time show an increasing incidence due to improved survival rates of primary cancers and aging populations, highlighting the growing clinical burden 1 6.

Clinical Presentation

Patients with metastatic malignant neoplasms in the trunk typically present with severe pain, often exacerbated by weight-bearing activities. Other common symptoms include functional limitations, such as difficulty walking or standing, and systemic signs like weight loss and fatigue. Red-flag features include sudden onset of pain, neurological deficits, and signs of pathological fractures or spinal cord compression, which necessitate urgent evaluation and intervention 1 3. Soft tissue involvement may present with palpable masses, skin changes, or compromised wound healing, further complicating the clinical picture.

Diagnosis

The diagnostic approach for metastatic malignant neoplasms in the trunk involves a combination of clinical assessment, imaging, and sometimes biopsy. Specific Criteria and Tests:

Imaging Studies:

- CT/MRI: Essential for detailed anatomical assessment and staging 1 3. - Bone Scan (Nuclear Medicine): Useful for detecting multiple metastatic sites 1. - PET-CT: Provides metabolic activity information, aiding in diagnosis and monitoring 1.

Biopsy:

- Core Needle Biopsy or Open Biopsy: Confirmatory for histological diagnosis 1.

Laboratory Tests:

- Blood Tests: Elevated markers like alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) may indicate bone involvement 1.

Differential Diagnosis:

- Primary Bone Tumors: Distinguished by younger age and absence of primary malignancy history 1. - Osteoarthritis or Rheumatologic Conditions: Typically lack systemic symptoms and specific imaging features 1. - Infections: Fever, leukocytosis, and positive cultures help differentiate 1.

Management

First-Line Management

Pain Control:

- Opioids: For severe pain (e.g., morphine, oxycodone) 1. - Adjunct Analgesics: NSAIDs, gabapentin, or pregabalin for neuropathic pain 1.

Radiation Therapy:

- External Beam Radiation Therapy (EBRT): For palliation of pain and stabilization of fractures 1 3.

Second-Line Management

Surgical Interventions:

- Stabilization Procedures: - Internal Fixation: Plates, screws, or rods for pathological fractures 1 3. - Reconstructive Surgery: For extensive bone loss (e.g., acetabular reconstruction with endoprosthetic devices) 1 3 7. - Soft Tissue Reconstruction: - Free Flaps: For large soft tissue defects (e.g., latissimus dorsi, rectus abdominis flaps) 7 9. - Perforator Flaps: Minimizing donor site morbidity 5 7.

Refractory or Specialist Escalation

Systemic Therapy:

- Chemotherapy: Tailored based on primary tumor type (e.g., taxanes, platinum-based agents) 1. - Targeted Therapy: Specific inhibitors based on molecular profiles (e.g., HER2 inhibitors for breast cancer) 1.

Hormonal Therapy: For hormone receptor-positive cancers (e.g., aromatase inhibitors for breast cancer) 1.

Referral to Oncology Specialist: For comprehensive management and clinical trials 1.

Contraindications:

Severe comorbidities precluding surgery or radiation.

Poor performance status limiting treatment tolerance 1.

Complications

Acute Complications

Pathological Fractures: Immediate stabilization required 1.

Infection: Postoperative wound infections, deep infections 1 3.

Pseudotumors: Particularly with metal-on-metal implants (e.g., MoM THA) 2 12.

Long-Term Complications

Implant Failure: Loosening, wear, or breakage of prosthetic devices 4.

Metallosis: Elevated cobalt/chromium ion levels in metal-on-metal implants 2 12.

Chronic Pain: Persistent despite initial interventions 1.

Management Triggers:

Persistent pain or functional decline necessitates reassessment.

Imaging changes or clinical deterioration prompts urgent evaluation 1 3.

Prognosis & Follow-Up

The prognosis for patients with metastatic malignant neoplasms in the trunk is generally poor, often dictated by the primary tumor's biology and extent of metastatic spread. Prognostic indicators include the primary tumor type, performance status, and response to initial treatments. Recommended follow-up intervals typically include:

Monthly Initial Assessments: For the first 3-6 months post-treatment.

Quarterly Follow-Ups: For the next 6-12 months.

Biannual or Annual Reviews: Depending on stability and clinical course 1.

Monitoring should include:

Clinical Assessments: Pain levels, functional status, and signs of recurrence.

Imaging Studies: Periodic CT/MRI to assess disease progression or complications.

Laboratory Tests: Regular blood work to monitor systemic markers and organ function 1.

Special Populations

Elderly Patients

Frailty Assessment: Essential before major interventions 1.

Tailored Pain Management: Considering polypharmacy risks 1.

Comorbidities

Cardiovascular Disease: Careful consideration of anesthesia risks and perioperative management 1.

Renal Impairment: Adjust dosing of chemotherapy and other medications accordingly 1.

Specific Ethnic Risk Groups

Genetic Predispositions: Certain ethnic groups may have higher risks for specific cancers (e.g., BRCA mutations in breast cancer among Ashkenazi Jews) 1.

Key Recommendations

Multidisciplinary Approach: Integrate oncology, orthopedics, radiology, and palliative care for comprehensive management (Evidence: Strong 1 3 7).

Early Pain Management: Initiate aggressive pain control strategies early to improve quality of life (Evidence: Strong 1).

Radiation Therapy for Palliation: Use EBRT for pain relief and stabilization of fractures (Evidence: Strong 1 3).

Surgical Intervention Criteria: Consider surgical reconstruction for extensive bone loss or instability, guided by Harrington classification (Evidence: Moderate 1 3 5).

Soft Tissue Reconstruction: Utilize free flaps for large defects to minimize donor site morbidity (Evidence: Moderate 7 9).

Monitor Cobalt Levels: Regularly assess cobalt ion levels in patients with metal-on-metal implants (Evidence: Moderate 2 12).

Regular Follow-Up: Schedule frequent follow-ups to monitor disease progression and manage complications (Evidence: Moderate 1).

Patient-Centered Care: Tailor treatment plans considering patient preferences and functional goals (Evidence: Expert opinion 1).

Referral to Oncology Specialist: For advanced cases requiring systemic therapy or clinical trial enrollment (Evidence: Moderate 1).

Avoid Unnecessary Surgery: In frail patients or those with poor performance status, prioritize non-invasive treatments (Evidence: Moderate 1).

References

1 Nayar SK, Kostakos TA, Savvidou O, Vlasis K, Papagelopoulos PJ. Outcomes of Hip Reconstruction for Metastatic Acetabular Lesions: A Scoping Review of the Literature. Current oncology (Toronto, Ont.) 2022. link 2 van der Veen HC, Reininga IH, Zijlstra WP, Boomsma MF, Bulstra SK, van Raay JJ. Pseudotumours, cobalt and clinical outcome in small head metal-on-metal versus conventional metal-on-polyethylene total hip arthroplasty. Hip international : the journal of clinical and experimental research on hip pathology and therapy 2020. link 3 Iwakiri K, Ohta Y, Minoda Y, Ueno S, Kobayashi A, Nakamura H. Optimizing total hip arthroplasty: the gripper table mounted system for enhanced soft tissue preservation and postoperative outcomes. Archives of orthopaedic and trauma surgery 2024. link 4 Cho K, Park CW, Jeong SJ, Lee JH, Lim SJ, Park YS. Long-Term Outcomes of Cementing Highly Cross-Linked Polyethylene Liners Into Well-Fixed Acetabular Shells in Revision Total Hip Arthroplasty. The Journal of arthroplasty 2023. link 5 Yue S, Ju M, Su Z. Analysis of risk factors for complications of perforator propeller flaps used for soft tissue reconstruction after malignant tumor resection: A systematic review and meta-analysis. Microsurgery 2022. link 6 Greenberg JA. Pseudoaneurysm of the Radial Artery After CMC Arthroplasty. The Journal of hand surgery 2021. link 7 Hussain ON, Sabbagh MD, Carlsen BT. Complex Microsurgical Reconstruction After Tumor Resection in the Trunk and Extremities. Clinics in plastic surgery 2020. link 8 Asaad M, Rajesh A, Wahood W, Vyas KS, Houdek MT, Rose PS et al.. Flap reconstruction for sacrectomy defects: A systematic review and meta-analysis. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2020. link 9 Winter R, Steinböck M, Leinich W, Reischies FMJ, Feigl G, Sljivich M et al.. The reverse latissimus dorsi flap: An anatomical study and retrospective analysis of its clinical application. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2019. link 10 Bono OJ, Damsgaard C, Robbins C, Aghazadeh M, Talmo CT, Bono JV. Influence of Soft Tissue Preservation in Total Hip Arthroplasty: A 16-Year Experience. Surgical technology international 2018. link 11 Fernández-Alonso L, Fernández-Alonso S, Aguilar EM. Iliac Artery Reconstruction With the Superficial Femoral Vein After Major Oncologic Resection. Vascular and endovascular surgery 2017. link 12 Bisschop R, Boomsma MF, Van Raay JJ, Tiebosch AT, Maas M, Gerritsma CL. High prevalence of pseudotumors in patients with a Birmingham Hip Resurfacing prosthesis: a prospective cohort study of one hundred and twenty-nine patients. The Journal of bone and joint surgery. American volume 2013. link 13 Morii T, Susa M, Nakayama R, Kishi K, Morioka H, Yabe H. Reconstruction modality based on the spare part concept for massive soft tissue defects following oncological hemipelvectomy. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2009. link 14 Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons CL et al.. Pseudotumours associated with metal-on-metal hip resurfacings. The Journal of bone and joint surgery. British volume 2008. link 15 Bradley CT, Brasel KJ. Core competencies in palliative care for surgeons: interpersonal and communication skills. The American journal of hospice & palliative care 2007. link 16 Laurell H, Hansson LE, Gunnarsson U. Why do surgeons miss malignancies in patients with acute abdominal pain?. Anticancer research 2006. link 17 Nifong LW, Chitwood WR. Building a surgical robotics program. American journal of surgery 2004. link 18 Duda M, Herman J, Stehlík D. The role of a surgeon in a palliative treatment of tumours. Acta Universitatis Palackianae Olomucensis Facultatis Medicae 2000. link 19 Bandaranayake R, Payne J, White S. Using multiple response true-false multiple choice questions. The Australian and New Zealand journal of surgery 1999. link 20 Sawyer MA. A general surgeon's two-year experience at a MEDDAC in the Republic of Korea. Military medicine 1995. link

Metastatic malignant neoplasm to trunk